LOS ANGELES, Sept. 25, 2025 (GLOBE NEWSWIRE) -- Glancy Prongay & Murray LLP reminds investors of the upcoming October 10, 2025 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired SelectQuote, Inc. (“SelectQuote” or the “Company”) (NYSE: SLQT) securities between September 9, 2020 and May 1, 2025, inclusive (the “Class Period”). IF YOU SUFFERED A LOSS ON YOUR SELECTQUOTE INVESTMENTS, CLICK HERE TO INQUIRE ABOUT POTENTIALLY PURSUING CLAI ...

Core Viewpoint - A class action lawsuit has been filed against SelectQuote, Inc. for allegedly violating the False Claims Act by directing Medicare beneficiaries to insurers that compensated the company the most, rather than providing unbiased comparisons of insurance plans [2][3]. Group 1: Allegations Against SelectQuote - The complaint alleges that SelectQuote failed to disclose that it directed Medicare beneficiaries to plans based on compensation rather than quality [2]. - It is claimed that SelectQuote did not provide unbiased comparison shopping for Medicare Advantage plans and received illegal kickbacks from insurers [2]. - The U.S. Department of Justice filed a complaint stating that SelectQuote received "tens of millions of dollars" in illegal kickbacks from 2016 to at least 2021 [3]. Group 2: Impact on Stock Price - Following the DOJ's allegations, SelectQuote's stock price fell by $0.61, or 19.2%, closing at $2.56 per share on May 1, 2025 [3]. Group 3: Class Action Participation - Shareholders interested in participating as lead plaintiffs in the class action must file their papers by October 10, 2025 [4]. - Shareholders can remain absent class members and still be eligible for recovery without participating in the case [4]. Group 4: Company Background - Robbins LLP is a law firm recognized for its work in shareholder rights litigation, helping shareholders recover losses and improve corporate governance since 2002 [5].

Core Viewpoint - A class action lawsuit has been filed against SelectQuote, Inc. for allegedly receiving illegal kickbacks from health insurance companies and misleading investors about its business practices [6]. Allegation Details - The U.S. Department of Justice filed a complaint against SelectQuote, alleging that from 2016 to at least 2021, the company received "tens of millions of dollars" in illegal kickbacks for steering Medicare beneficiaries to specific insurance plans [6]. - The lawsuit claims that SelectQuote made materially false statements and failed to disclose adverse facts about its operations, including directing beneficiaries to plans that compensated the company the most, rather than providing unbiased comparisons [6]. Stock Impact - Following the DOJ's announcement, SelectQuote's stock price dropped by $0.61, or 19.2%, closing at $2.56 per share on May 1, 2025, with unusually high trading volume [6]. Legal Process - Investors who purchased SelectQuote securities between September 9, 2020, and May 1, 2025, have until October 10, 2025, to apply to be appointed as lead plaintiff in the lawsuit [6].

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against SelectQuote, Inc. due to allegations of violating federal securities laws, with a deadline for investors to seek lead plaintiff status in a class action lawsuit by October 10, 2025 [2][4]. Group 1: Allegations Against SelectQuote - The complaint alleges that SelectQuote directed Medicare beneficiaries to plans that compensated the company the most, regardless of the quality of the plans [4]. - It is claimed that SelectQuote did not provide unbiased comparisons for Medicare Advantage insurance plans and received illegal kickbacks from insurers [4]. - The U.S. Department of Justice filed a complaint stating that SelectQuote received "tens of millions of dollars" in illegal kickbacks from 2016 to at least 2021 [5]. Group 2: Impact on Stock and Legal Proceedings - Following the DOJ's allegations, SelectQuote's stock price fell by $0.61, or 19.2%, closing at $2.56 per share on May 1, 2025, amid heavy trading volume [5]. - Investors who suffered losses exceeding $75,000 between September 9, 2020, and May 1, 2025, are encouraged to contact Faruqi & Faruqi to discuss their legal options [1][2].

OVERLAND PARK, Kan.--(BUSINESS WIRE)--SelectQuote, Inc. (NYSE: SLQT), leading distributor of Medicare insurance policies and owner of a rapidly growing Healthcare Services platform, today announced a significant milestone in its partnership with Findhelp, a closed-loop referral management software company at the forefront of powering the U.S. safety net. SelectQuote has directed more than 200,000 low-income seniors, and Findhelp has provided free and reduced-cost social services, addressing cri. ...

Group 1 - SelectQuote, Inc. is facing a federal securities class action, with a deadline of October 10, 2025, for investors to seek the role of lead plaintiff [1] - Investors who purchased or acquired SelectQuote securities are encouraged to contact Kirby McInerney LLP for more information regarding their rights [1] - The announcement highlights the importance of the upcoming deadline for potential plaintiffs in the case [1]

Core Insights - Class actions have been initiated for stockholders of Altimmune, Inc. and SelectQuote, Inc. with deadlines for lead plaintiff petitions approaching [1] Altimmune, Inc. (NASDAQ:ALT) - The class period for Altimmune is from August 10, 2023, to June 25, 2025, with a lead plaintiff deadline of October 6, 2025 [2] - On June 26, 2025, Altimmune announced disappointing results from the IMPACT Phase 2b MASH trial of Pemvidutide, failing to achieve statistical significance in the primary endpoint of fibrosis reduction due to a higher-than-expected placebo response [2] - Following the announcement, Altimmune's stock price plummeted from $7.71 to $3.61 per share, marking a decline of 53.2% in one day [3] SelectQuote, Inc. (NYSE:SLQT) - The class period for SelectQuote is from September 9, 2020, to May 1, 2025, with a lead plaintiff deadline of October 10, 2025 [3] - On May 1, 2025, the U.S. Department of Justice filed a complaint against SelectQuote, alleging the company received "tens of millions of dollars" in illegal kickbacks from health insurance companies from 2016 to 2021 [3] - The complaint claims SelectQuote misled Medicare beneficiaries by stating it offered unbiased coverage comparisons while actually directing them to plans that paid SelectQuote the most, resulting in a stock price drop of $0.61, or 19.2%, to close at $2.56 per share on the same day [3][4]

Core Viewpoint - Rosen Law Firm is reminding investors who purchased SelectQuote, Inc. securities between September 9, 2020, and May 1, 2025, of the October 10, 2025, deadline to become lead plaintiffs in a class action lawsuit [1] Group 1: Class Action Details - Investors who purchased SelectQuote securities during the specified Class Period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [1] - A class action lawsuit has already been filed, and interested parties can join by submitting a form or contacting the law firm [2][5] - The lead plaintiff must file a motion with the Court by October 10, 2025, to represent other class members in the litigation [2] Group 2: Law Firm Credentials - Rosen Law Firm emphasizes the importance of selecting qualified counsel with a successful track record in securities class actions [3] - The firm has achieved significant settlements, including the largest securities class action settlement against a Chinese company at the time and has been ranked highly for its performance in securities class action settlements [3] - In 2019, the firm secured over $438 million for investors, showcasing its capability in recovering funds for clients [3] Group 3: Allegations Against SelectQuote - The lawsuit alleges that SelectQuote made false and misleading statements and failed to disclose critical information regarding its business practices [4] - Specific allegations include directing Medicare beneficiaries to insurers that compensated SelectQuote, not providing unbiased comparisons, receiving illegal kickbacks, and non-compliance with laws and regulations [4] - The lawsuit claims that these actions led to misleading positive statements about SelectQuote's business, resulting in investor damages when the truth was revealed [4]

Core Viewpoint - SelectQuote Inc. is facing significant legal challenges following a whistleblower lawsuit alleging deceptive sales practices, which has resulted in a 19% drop in its share price and a subsequent class-action lawsuit from investors [1][4]. Legal Issues - The U.S. Department of Justice (DOJ) has intervened in a lawsuit against SelectQuote, claiming the company misrepresented its Medicare Advantage sales practices and received improper payments from 2016 to 2021 [3][7]. - The class-action lawsuit, Pahlkotter v. SelectQuote Inc. et al., includes investors who purchased stock between September 9, 2020, and May 1, 2025, alleging that SelectQuote misled the market regarding its business model and regulatory risks [2][5]. Market Reaction - Following the DOJ's involvement, SelectQuote's stock experienced a nearly 20% decline in a single day, and shares have fallen over 40% in the past six months due to investor concerns about legal exposure and reputational damage [4][5]. Allegations of Misconduct - The lawsuit claims that SelectQuote directed customers towards higher-commission plans, accepted illegal kickbacks, and violated federal statutes, including the False Claims Act [6][7]. - Hagens Berman is investigating whether SelectQuote's revenue was artificially inflated through deceptive practices, suggesting that the company's claims of providing "unbiased advice" may have been misleading [6].

Core Viewpoint - SelectQuote, Inc. is facing a securities fraud class action lawsuit, and investors who have suffered losses are encouraged to contact legal representation to discuss their rights [1] Group 1 - Investors have until October 10, 2025, to request the Court to appoint them as lead plaintiff in the lawsuit [1]